Exendin-4 Loaded Nanoparticles with a Lipid Shell and Aqueous Core Containing Micelles for Enhanced Intestinal Absorption.
J Biomed Nanotechnol · 2015
Last updated 2026-05-28In this study, researchers created a special type of nanoparticle designed to deliver exendin-4, a GLP-1 drug, by mouth. The nanoparticles were 97.7% efficient at trapping the drug and improved its absorption in lab tests. In mice with diabetes, these nanoparticles lowered blood sugar levels, achieving 12.7% of the effect seen with injected exendin-4.
AI summary of the abstract below.
| Journal | J Biomed Nanotechnol, 2015 |
|---|---|
| Citations | 25 |
| Relative citation ratio | 1.12 |
| NIH percentile | 54 |
| Molecules | — |
Abstract
The purpose of this study was to formulate nanoparticles with an elaborate structure for oral delivery of exendin-4 using a simple preparation process. The nanoparticles possessed a mixed lipid shell and an aqueous core which contained drug-loaded micelles. Formulation was optimized by a central composite design and the structure of the nanoparticles was validated. The efficacy for delivery of exendin-4 was evaluated both in vitro and in vivo. The drug encapsulation efficiency of the nanoparticles reached 97.7%. The nanoparticles greatly enhanced the cellular uptake and transport of encapsulated exendin-4 in vitro. The in situ study showed that exendin-4 could be transported across the epithelium into intestinal capillaries, while the lipid materials largely remained in the epithelium. Pharmacodynamic studies in diabetic KKAy mice demonstrated that the exendin-4-loaded nanoparticles exhibited a marked hypoglycemia effect with a pharmacological availability of 12.7% after intestinal administration.
Verbatim abstract via PubMed 26349398 ↗